Partnership working helps create miscarriage support tool

An online tool was developed to help women who have had a miscarriage understand their chance of a successful pregnancy, as well as access personalised advice on tests, treatment and lifestyle changes. Knowledge exchange was crucial in the tool's development, which was created by Warwick academics in partnership with Tommy’s National Centre for Miscarriage Research. The team analysed data and created an algorithm to help predict miscarriage. By collecting this data, the tool also now plays a valuable part in helping understand some of the factors that increase miscarriage risk. Read more...

National Grid and WMS work together to improve construction worker wellbeing

The construction industry has the highest number of deaths by suicide compared to other employment sectors. To help address this, research and knowledge exchange between Warwick Medical School and National Grid led to the development of a Health Hub for employees - set up by National Grid on a construction site Kent. The Health Hub, a pilot for future projects which could be implemented UK-wide, included a gym, social spaces, one-to-one wellbeing coaching and a canteen with free healthy meals. Initial findings suggest that workers who used the hub and its facilities had significantly lower anxiety scores. Read more...

Transforming how cells and cell-based therapies are stored and transported

CryoLogyx, a University of Warwick spin-out company, uses pioneering chemistry research to transform how cells, and cell-based therapies, are stored and transported. Researchers created new macromolecular cryoprotectants, allowing cells to survive the freezing process and to replace organic solvents currently used. CryoLogyx uses the technology to transform cell-based therapies, simplify medicine development and aid supply chains, whilst protecting biological materials during freezing. In 2021, CryoLogyx, received further investment from Oxford Technology Management, private investors and Innovate UK. Read more...

Developing medicinal patches to delivery drugs through the the skin

Medherant was founded in 2014 to commercialise research into polymeric bioadhesives, and in 2015 the company signed a license agreement with Bostik, to support Medherant's capabilities to develop drug delivery through medicinal patches applied to the skin. Knowledge exchange and partnership working with Bostik led to clinical trials (in 2015) to explore the effectiveness of the drugs moving into the body from the skin. Medherant was supported by The Science Cities Research Alliance, a University of Warwick initiative which has seen a number of spinout companies formed to commercialise successful Warwick research findings. Read more...

Developing new technologies to improve cancer diagnosis and treatments

A research collaboration between Warwick and University Hospitals Coventry and Warwickshire led to the development of a new technology which will speed up the diagnoses of cancer and improve treatment for cancer patients. Using artificial intelligence, the technology will analyse tissue samples from people with suspected cancer and accelerate diagnosis by functioning even when the pathologist is unavailable. The team of Warwick academics and hospital consultant pathologists worked with Warwick Innovations to form a spinout company, Histofy Ltd, that will further develop the technology into software that can be used in cancer labs globally. Read more...

Warwick involved in Megalab which helped bolster fight against Covid-19

Warwick played a central role in the UK's first megalab (the Rosalind Franklin Laboratory in Leamington Spa). The lab was part of the country's early 'test and trace' infrastructure in 2021. A significant number of Warwick staff and research students with laboratory skills were deployed to the megalab. The exchange and sharing of knowledge was particularly critical during the Covid-19 pandemic, and the lab helped boost the science industry and provide employment in the local area. As well as processing Covid-19 tests, the lab also played a vital role in responding to new variants of the virus. Read more...

Delivering the future of intracellular medicine

NanoSyrinx is a synthetic biology spinout company originating from Warwick Medical School. It is creating technology for targeted intracellular delivery of biological molecules. Most drugs don't traverse the body well, limiting their effectiveness. It's an even greater problem for drugs such as antibodies and peptides, with new delivery models sorely needed. Collaboration and knowledge exchange helped cement the success of NanoSyrinx, which was built on Co-Founder & CEO Dr Joe Healy's research during his Warwick PhD. It was supported by Midlands ICURe (Innovation to Commercialisation of University Research) which supports researchers with commercially-promising ideas. Read more...

Back to case studies homepage